MSA Treatment Approaches and Emerging Therapies

MSA Treatment Approaches and Emerging Therapies

Multiple System Atrophy ([MSA](/diseases/multiple-system-atrophy)) remains one of the most challenging neurodegenerative disorders to treat. The multi-system involvement and rapid progression demand a comprehensive approach combining symptomatic management, supportive care, and emerging disease-modifying strategies. This page reviews current treatment paradigms and promising therapeutic avenues.

Pathophysiology Overview

MSA is a progressive neurodegenerative disorder characterized by autonomic failure in combination with parkinsonian or cerebellar features. The disease is classified into two main subtypes: MSA-P (predominant parkinsonism) and MSA-C (predominant cerebellar ataxia) [@krismer2023]. Pathologically, MSA is defined by the presence of glial cytoplasmic inclusions ([GCIs](/mechanisms/msa-genetics-risk-factors)) composed of aggregated [α-synuclein](/proteins/alpha-synuclein) within [oligodendrocytes](/cell-types/oligodendrocytes), which distinguishes it from [Parkinson's disease](/diseases/parkinson-disease) where [Lewy bodies](/proteins/alpha-synuclein) primarily affect neurons [@jellinger2023].

MSA Treatment Approaches and Emerging Therapies

Multiple System Atrophy ([MSA](/diseases/multiple-system-atrophy)) remains one of the most challenging neurodegenerative disorders to treat. The multi-system involvement and rapid progression demand a comprehensive approach combining symptomatic management, supportive care, and emerging disease-modifying strategies. This page reviews current treatment paradigms and promising therapeutic avenues.

Pathophysiology Overview

MSA is a progressive neurodegenerative disorder characterized by autonomic failure in combination with parkinsonian or cerebellar features. The disease is classified into two main subtypes: MSA-P (predominant parkinsonism) and MSA-C (predominant cerebellar ataxia) [@krismer2023]. Pathologically, MSA is defined by the presence of glial cytoplasmic inclusions ([GCIs](/mechanisms/msa-genetics-risk-factors)) composed of aggregated [α-synuclein](/proteins/alpha-synuclein) within [oligodendrocytes](/cell-types/oligodendrocytes), which distinguishes it from [Parkinson's disease](/diseases/parkinson-disease) where [Lewy bodies](/proteins/alpha-synuclein) primarily affect neurons [@jellinger2023].

The underlying pathogenesis involves a complex interplay between [α-synuclein](/proteins/alpha-synuclein) pathology, [oligodendrocyte](/cell-types/oligodendrocytes) dysfunction, and neuronal degeneration [@muller2023]. The selective vulnerability of [oligodendrocytes](/cell-types/oligodendrocytes) in MSA makes it unique among α-synucleinopathies, as these myelin-producing cells fail to properly support neurons, leading to widespread [white matter](/mechanisms/demyelination) dysfunction and progressive neurological decline.

Clinical Features and Natural History

Disease Progression

MSA typically presents in the sixth decade of life with a median survival of 6-10 years from symptom onset [@krismer2023]. The rapid progression distinguishes [MSA](/diseases/multiple-system-atrophy) from [Parkinson's disease](/diseases/parkinson-disease), where patients may maintain function for decades. Early [autonomic dysfunction](/mechanisms/autonomic-dysfunction-neurodegeneration)—including [orthostatic hypotension](/biomarkers/orthostatic-hypotension), urinary urgency, and [REM sleep behavior disorder](/mechanisms/rem-sleep-behavior-disorder)—often precedes motor symptoms by years.

| Disease Stage | Typical Features | Median Time from Onset |
|--------------|-----------------|----------------------|
| Prodromal | RBD, OH, urinary symptoms | 0-2 years |
| Early | Motor symptoms, autonomic dysfunction | 2-4 years |
| Mid | Disability, fall risk | 4-6 years |
| Advanced | Severe disability, dysphagia | 6-8 years |

Motor Manifestations

Parkinsonian Features (MSA-P):

• Bradykinesia with rigidity
• Resting tremor (less common than PD)
• Poor levodopa response
• Early postural instability

• Gait ataxia with wide-based stance
• Limb dysmetria
• Scanning speech
• Oculomotor abnormalities

Symptomatic Management

Motor Symptoms

[Levodopa](/therapeutics/levodopa)/Carbidopa:

• Efficacy: Modest benefit in ~30% of patients [@espay2020]
• Response pattern: Often transient (months), rarely sustained
• Dose: Up to 1000 mg/day (often poorly tolerated)
• Side effects: [Orthostatic hypotension](/biomarkers/orthostatic-hypotension), confusion, hallucinations
• Note: Poor response helps distinguish from [PD](/diseases/parkinson-disease)

• Pramipexole, ropinirole, rotigotine
• Limited efficacy in MSA
• Often poorly tolerated due to orthostatic hypotension

• Amantadine: May provide modest benefit for some patients
• Zonisamide: Limited evidence, not recommended
• Botulinum toxin: For cervical dystonia when present

Autonomic Dysfunction

Orthostatic Hypotension:

[Orthostatic hypotension](/biomarkers/orthostatic-hypotension) represents one of the most debilitating symptoms in MSA, affecting over 70% of patients [@kaufmann2020]. The pathophysiology involves failure of sympathetic baroreflexes, leading to inadequate vasoconstriction upon standing.

| Treatment | Mechanism | Dose | Notes |
|-----------|-----------|------|-------|
| [Midodrine](/therapeutics/midodrine) | α1-adrenergic agonist | 5-10 mg TID | Monitor supine hypertension |
| [Droxidopa](/therapeutics/droxidopa) | Norepinephrine prodrug | 100-600 mg TID | FDA approved for OH |
| Fludrocortisone | Mineralocorticoid | 0.1-0.3 mg daily | Monitor fluid retention |
| Pyridostigmine | Acetylcholinesterase | 30-60 mg TID | Adjunct therapy |
| Compression stockings | External compression | Full leg | Practical but limited |

Supine Hypertension:

• Nighttime head elevation (30°)
• Evening dose reduction of midodrine/droxidopa
• Consider short-acting antihypertensives if severe
• Clonidine patch may help manage nocturnal hypertension

Urinary symptoms in MSA reflect both detrusor overactivity and impaired sphincter control:

• Oxybutynin: Anticholinergic for detrusor overactivity
• Tamsulosin: α-blocker for outlet obstruction (if applicable)
• Intermittent catheterization for retention
• Desmopressin: For nocturnal polyuria (use with caution)

• PDE5 inhibitors may help erectile dysfunction
• Referral to sexual health specialist for comprehensive management

Sleep Disorders

Sleep disturbances are extremely common in MSA and often precede motor symptoms [@fogel2022]:

REM Sleep Behavior Disorder:

• [Clonazepam](/therapeutics/clonazepam): 0.25-1.0 mg at bedtime
• [Melatonin](/therapeutics/melatonin-neurodegeneration): 3-12 mg at bedtime
• Safety measures: Bed padding, remove sharp objects

• CPAP titration if obstructive
• Monitoring for central sleep apnea (more common in MSA)
• Positional therapy may help

• Monitor for stridor during sleep
• May require tracheostomy in severe cases
• ENT evaluation for airway assessment

Emerging Disease-Modifying Therapies

Alpha-Synuclein Targeting

Given MSA is an [α-synucleinopathy](/diseases/alpha-synucleinopathies), several approaches target pathological [protein](/proteins/alpha-synuclein) [@kiyota2023]:

Immunotherapy:

• Active immunization: Vaccines targeting aggregated α-synuclein (e.g., Affitope PD01A)
• Passive immunization: Monoclonal antibodies (e.g., BLA1, PRX004, cinpanemab)
• Challenge: Limited penetration of blood-brain barrier, variable patient response

• Small molecules preventing [α-synuclein](/proteins/alpha-synuclein) oligomerization
• NPT200-1, Anle138b in development
• Target early in disease course

• ASO targeting SNCA gene expression
• siRNA delivery to reduce [α-synuclein](/proteins/alpha-synuclein) production
• Gene therapy approaches [@vilas2022]

Neuroprotective Strategies

Cellular Protection:

• BDNF/GDNF: Promote neuron survival via neurotrophic factor delivery
• CoQ10: [Mitochondrial](/mechanisms/mitochondrial-dysfunction) support (mixed trial results)
• Vitamin D: Neuroprotective effects under investigation

• Minocycline: Mixed results in clinical trials
• TNF-α inhibitors: Under exploration
• Microglial activation modulators [@volpe2023]

Oligodendrocyte-Targeted Therapies

Unique to MSA as an [oligodendrogliopathy](/cell-types/oligodendrocytes) [@lefevre2023]:

• Remyelination strategies: Promote oligodendrocyte precursor cell differentiation
• Myelin stabilization: Prevent demyelination cascade
• Metabolic support: Enhance oligodendrocyte energy metabolism
• α-Synuclein clearance from [oligodendrocytes](/cell-types/oligodendrocytes): Target GCI formation

Clinical Trial Landscape

Active Trials (2024-2025)

| Agent | Target | Phase | Status | Notes |
|-------|--------|-------|--------|-------|
| Cinpanemab | [α-syn](/proteins/alpha-synuclein) | Phase 2 | Completed | Biogen |
| Prasinezumab | [α-syn](/proteins/alpha-synuclein) | Phase 2 | Completed | Roche |
| UCB0599 | [α-syn](/proteins/alpha-synuclein) oligomer | Phase 2 | Ongoing | UCB |
| Aziravir | Gene therapy | Phase 1 | Recruiting | AAV vector |
| ND0612 | [Levodopa](/therapeutics/levodopa) | Phase 3 | Ongoing | Continuous infusion |

Failed Approaches

Understanding negative trials is critical for future development:

• Lithium: No benefit in Phase 2 [@krismer2023]
• Riluzole: No disease modification
• Ivabradine: Failed for cardiovascular symptoms
• Minocycline: Negative in Phase 2/3
• CoQ10: Negative in large trial

Surgical Interventions

Deep Brain Stimulation (DBS):

DBS has limited utility in MSA compared to [Parkinson's disease](/diseases/parkinson-disease) [@cilia2023]:

• Target selection: Subthalamic nucleus (STN) or globus pallidus interna (GPi)
• Patient selection: Critical — only patients with good levodopa response considered
• Outcomes: More modest than in PD, variable results
• Risks: Higher complication rate due to autonomic dysfunction
• Considerations: Must rule out MSA before considering DBS

Continuous drug delivery systems under investigation:

• Levodopa-carbidopa intestinal gel (LCIG): Continuous duodenal infusion
• Apomorphine continuous subcutaneous infusion: For advanced motor symptoms
• Trial data: Limited in MSA population

Experimental Approaches

Gene Therapy Strategies:

• AAV-mediated gene delivery: Targeting neurotrophic factors
• SNCA knockdown: Reducing alpha-synuclein expression
• Antisense oligonucleotide delivery: Direct brain administration

• Mesenchymal stem cells (MSCs): Neuroprotective potential
• Oligodendrocyte precursor cell transplantation: Remyelination approaches
• Neural stem cells: Replacement therapy

• Autophagy enhancers: Rapamycin, trehalose
• Iron chelators: Deferoxamine, clioquinol
• Urate elevation: Neuroprotective approach

Biomarker Development

Accurate diagnosis and disease monitoring require biomarkers [@watabe2023]:

• Neuroimaging: MR planimetry, DTI, PET tracers
• Fluid biomarkers: Neurofilament light chain (NfL), α-synuclein SAA
• Neurophysiology: Skin biopsy for autonomic testing

Supportive and Rehabilitation

Physical Therapy

• Balance training: Reduce fall risk
• Gait training: Improve mobility and prevent freezing
• Strength training: Maintain function and prevent sarcopenia
• Stretching: Manage contractures
• Aquatic therapy: Low-impact exercise option

Speech and Swallowing

Speech and swallowing disorders affect over 90% of MSA patients:

• LSVT LOUD: Voice therapy for dysarthria
• Swallowing assessment: Video fluoroscopy
• Diet modification: Texture modifications as needed
• Lee Silverman Voice Treatment: May improve vocal loudness

Occupational Therapy

• Home safety assessment
• Adaptive equipment
• Energy conservation techniques
• Wheelchair seating assessment

Nutritional Support

• Weight monitoring (unintended weight loss common)
• Dietary consultation for dysphagia
• Vitamin supplementation when needed
• Hydration management

Palliative Considerations

Advanced Disease

• Dysphagia management: PEG tube consideration when oral intake inadequate
• Communication aids: Speech-generating devices for severe dysarthria
• Pain management: Neuropathic pain protocols
• Caregiver support: Respite care, support groups, education
• Advance care planning: Early discussion of care preferences

End-of-Life Planning

• Advance care directives
• Goals of care discussions
• Hospice involvement when appropriate
• Family support and counseling
• Symptom management at end of life

Emerging Therapeutic Approaches

Alpha-Synuclein-Targeted Therapies

Immunotherapy approaches targeting pathological alpha-synuclein represent the most advanced disease-modifying strategy:

Active Immunization:

• ACI-35: Phosphoserine liposome-based vaccine (Phase 1/2)
• UB-311: Synthetic peptide vaccine (Phase 1)
• Generates antibodies against pathological alpha-synuclein

• Pemiselimab (BIIB054): Anti-alpha-synuclein antibody (Phase 2)
• Lu AF87908: Antibody targeting aggregated alpha-synuclein (Phase 1)
• PRX004: Antibody targeting toxic oligomers (Phase 1)

Aggregation Inhibitors

Small molecules preventing alpha-synuclein aggregation:

| Agent | Mechanism | Development Stage |
|-------|-----------|-------------------|
| Anle138b | Oligomer modulator | Phase 1/2 |
| S-als3 | RNAse inhibitor | Preclinical |
| EGCG | Aggregate binding | Phase 2 |
| Curcumin | Aggregate disruption | Phase 2 |

Oligodendrocyte-Targeted Therapies

Protecting and regenerating oligodendrocytes is central to MSA treatment:

Neurotrophic Factors:

• GDNF: Promotes oligodendrocyte survival (intraparenchymal delivery)
• BDNF: Supports myelination (AAV-mediated)
• CNTF: Protects against demyelination

• Clemastine: Promotes OPC differentiation (Phase 2)
• Anti-LINGO-1: Block inhibitory signaling (Phase 2)
• Retinoic acid: Enhances remyelination (Preclinical)

Gene Therapy Approaches

Viral vector delivery of therapeutic genes:

Gene Silencing:

• SNCA-targeted siRNA via AAV
• Antisense oligonucleotides (ASOs)
• CRISPR-based approaches

• GBA gene delivery for lysosomal function
• COQ2 for mitochondrial function

Clinical Trial Landscape

Active Trials in MSA

Current therapeutic trials targeting various mechanisms:

| Trial | Agent | Mechanism | Phase |
|-------|-------|-----------|-------|
| NCT06035886 | ABBV-0805 | Alpha-synuclein antibody | Phase 1 |
| NCT05307848 | Masitinib | CSF-1R inhibitor | Phase 3 |
| NCT05423368 | Ampreloxetine | Norepinephrine reuptake | Phase 3 |
| NCT05122091 | CoQ10 | Mitochondrial support | Phase 2 |

Challenges in Clinical Development

Key obstacles to successful clinical trials include:

Future Directions

Precision Medicine Approaches

• Biomarker development: Earlier diagnosis through fluid and imaging biomarkers
• Genotype stratification: Personalized treatment based on genetic risk
• Stage-appropriate therapy: Match treatment to disease stage
• Subtype-specific interventions: MSA-P vs MSA-C targeting

Combination Strategies

• Multiple targets simultaneously (α-syn + oligodendrocyte + neuroinflammation)
• Symptomatic + disease-modifying approaches
• Sequential treatment approaches based on disease stage
• Multi-modal rehabilitation plus pharmacotherapy

Research Priorities

Special Populations and Considerations

Pediatric and Young-Onset MSA

While MSA predominantly affects adults in their sixth decade, rare cases of early-onset MSA require special consideration:

Clinical Presentation:

• More aggressive disease course
• Greater cerebellar involvement
• Potentially different treatment responses

• Aggressive symptomatic treatment
• Genetic counseling for family planning
• Long-term care planning
• Psychosocial support for young patients

MSA in Different Ethnic Groups

Population-specific considerations affect treatment approaches:

European Populations:

• Higher prevalence of GBA variants
• Typical clinical presentation

• Higher proportion of MSA-C subtype
• Different COQ2 variant frequencies
• Modified treatment responses observed

• Limited epidemiological data
• Need for population-specific studies

Cost-Effectiveness Considerations

Economic Analysis of Treatments

Understanding the cost-effectiveness of interventions informs healthcare resource allocation:

High-Cost Interventions:

• Deep brain stimulation: $50,000-150,000 procedure
• Continuous drug infusion systems: $100,000+ annually
• Gene therapy: Potentially one-time high cost

• Annual medication costs: $5,000-20,000
• Assistive devices: $2,000-10,000
• Home care: $30,000-100,000 annually

Value-Based Treatment Selection

Prioritizing interventions based on cost-effectiveness:

• Midodrine for orthostatic hypotension: Highly cost-effective
• Physical therapy: Excellent value for fall prevention
• Speech therapy: Moderate cost for significant benefit
• Experimental treatments: Variable, based on outcomes

Novel Therapeutic Targets

Mitochondrial Protection

Given the prominent mitochondrial dysfunction in MSA, targeting mitochondrial health represents a promising approach:

Coenzyme Q10:

• Electron transport chain support
• Phase 3 trials ongoing
• Potential benefit for carriers of COQ2 variants

• Mitochondrial antioxidant
• Enhances insulin sensitivity
• Currently in preclinical evaluation

• Mitochondrial division inhibitor (mdivi-1)
• PINK1 activators
• Autophagy enhancers targeting mitochondria

Iron Chelation Therapy

Iron dysregulation contributes to oligodendrocyte vulnerability:

Chelation Approaches:

• Deferoxamine: Limited CNS penetration
• Clioquinol: Better BBB penetration
• VK-28: Novel iron chelator

• Phase 2 trials for neuroprotection
• Combination with antioxidants

Neurotrophic Factor Delivery

Supporting neuronal and glial survival through neurotrophic factors:

Growth Factor Therapy:

• GDNF: Promotes oligodendrocyte survival
• BDNF: Supports neuronal health
• CNTF: Prevents demyelination

• Intraparenchymal infusion
• AAV-mediated gene delivery
• Cell-based delivery systems

Patient Management Algorithms

Initial Assessment

Comprehensive evaluation at diagnosis:

Baseline Testing:

• Neurological examination with UMSARS
• Autonomic function testing
• MRI brain with specific sequences
• CSF analysis for biomarkers

• Movement disorders neurology
• Autonomic specialist
• Physical therapy
• Speech pathology
• Social work

Disease Progression Monitoring

Regular assessment to track progression:

Scheduled Follow-up:

• 3-month intervals in first year
• 6-month intervals thereafter
• Annual comprehensive evaluation

• Motor function (UMSARS)
• Autonomic symptoms
• Cognitive function
• Quality of life measures

Crisis Management

Recognition and management of acute complications:

Autonomic Crises:

• Severe orthostatic hypotension
• Urinary retention
• Respiratory compromise

• Falls with injury
• Dysphagia with aspiration
• Seizure activity

Long-Term Care Planning

Progressive disease requires advance planning:

Caregiver Considerations:

• Family education and training
• Respite care planning
• Support group connections
• Financial planning

• When home care becomes insufficient
• Nursing facility selection
• Specialized dementia care if needed

Emerging Research Frontiers

Prion-Like Propagation

Understanding alpha-synuclein transmission:

Mechanisms:

• Exosome-mediated transfer
• Direct cell-to-cell spread
• Template-driven aggregation

• Blocking propagation pathways
• Early intervention strategies
• Targeting seeding activity

Stem Cell Approaches

Cell replacement and regeneration:

Research Status:

• Preclinical safety established
• Efficacy being evaluated
• Manufacturing challenges remain

• Embryonic stem cells
• Induced pluripotent stem cells
• Mesenchymal stem cells

Biomarker-Driven Trials

Future clinical trials will increasingly use biomarkers:

Patient Selection:

• Genetic stratification (GBA, COQ2 carriers)
• Fluid biomarker enrichment
• Imaging marker selection

• NfL for disease progression
• Alpha-synuclein seeding assays
• Imaging measures of response

International Research Collaboration

Global efforts accelerate therapeutic development:

Consortia:

• MSA Coalition (United States)
• MSA Trust (United Kingdom)
• International MSA Working Group
• European Reference Networks

• Biobank repositories
• Clinical trial networks
• Registry databases

Conclusion

Treatment of MSA remains challenging due to poor understanding of disease mechanisms and limited therapeutic options. While current approaches focus on symptom management, the development of disease-modifying therapies targeting α-synuclein pathology and oligodendrocyte dysfunction offers hope for meaningful intervention. Comprehensive multidisciplinary care remains essential for optimizing quality of life in patients with MSA. Future success will depend on improved understanding of disease biology, development of reliable biomarkers, and implementation of precision medicine approaches tailored to individual patients.

References